BA Study of IMP4297 (20mg vs 10mg) in Healthy Male Subjects

NCT04351165 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: IMP4297

Sponsor

Impact Therapeutics, Inc.